Nuvalent (NASDAQ:NUVL) Stock Rating Lowered by Canaccord Genuity Group

Nuvalent (NASDAQ:NUVL) was downgraded by investment analysts at Canaccord Genuity Group from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

NUVL has been the subject of a number of other research reports. HC Wainwright lowered Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 price objective for the company. in a research note on Tuesday. Wells Fargo & Company reissued an “equal weight” rating and set a $124.00 price objective (up from $116.00) on shares of Nuvalent in a research note on Tuesday. Robert W. Baird set a $122.85 price objective on Nuvalent in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research note on Tuesday, April 21st. Finally, Barclays reissued an “equal weight” rating and set a $124.00 price objective (down from $152.00) on shares of Nuvalent in a research note on Tuesday. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $131.15.

Nuvalent Stock Performance

NASDAQ:NUVL opened at $123.35 on Tuesday. The firm has a market cap of $9.74 billion, a PE ratio of -20.35 and a beta of 1.15. Nuvalent has a fifty-two week low of $71.13 and a fifty-two week high of $123.62. The business has a 50 day moving average price of $103.44 and a 200-day moving average price of $103.19.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the previous year, the firm earned ($1.18) earnings per share. Research analysts predict that Nuvalent will post -5.74 EPS for the current year.

Insiders Place Their Bets

In related news, CEO James Richard Porter sold 30,000 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $88.53, for a total value of $2,655,900.00. Following the completion of the sale, the chief executive officer owned 324,879 shares of the company’s stock, valued at $28,761,537.87. This trade represents a 8.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Deborah Ann Miller sold 5,500 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total value of $593,120.00. Following the completion of the sale, the insider directly owned 59,634 shares of the company’s stock, valued at $6,430,930.56. The trade was a 8.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 126,953 shares of company stock worth $12,612,264. Insiders own 5.02% of the company’s stock.

Institutional Trading of Nuvalent

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its position in Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after buying an additional 108 shares during the period. Kennedy Capital Management LLC lifted its position in Nuvalent by 1.5% during the fourth quarter. Kennedy Capital Management LLC now owns 10,932 shares of the company’s stock valued at $1,100,000 after buying an additional 163 shares during the period. US Bancorp DE lifted its position in Nuvalent by 10.0% during the third quarter. US Bancorp DE now owns 2,070 shares of the company’s stock valued at $179,000 after buying an additional 188 shares during the period. EverSource Wealth Advisors LLC lifted its position in Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after buying an additional 195 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Nuvalent by 7.7% during the third quarter. Principal Financial Group Inc. now owns 3,290 shares of the company’s stock valued at $285,000 after buying an additional 234 shares during the period. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.